噬菌體市場規模、佔有率和成長分析（按產品類型、給藥途徑、分銷管道、應用、最終用途產業和地區分類）－2026-2033年產業預測

預計到 2024 年，全球噬菌體市場規模將達到 5,243 萬美元，到 2025 年將達到 5,542 萬美元，到 2033 年將達到 8,635 萬美元，預測期（2026-2033 年）的複合年成長率為 5.7%。

全球噬菌體市場正逐漸成為應對抗生素抗藥性和細菌感染疾病等緊迫挑戰的關鍵解決方案。噬菌體是一種靶向細菌的天然病毒，是傳統抗生素的一種極具前景的替代方案。抗生素抗藥性細菌的日益增加推動了人們對噬菌體療法的興趣，該療法以其高度特異性、對不斷進化的細菌菌株的適應性以及對有益微生物群影響極小而著稱。臨床前和臨床研究的良好結果也支持其治療潛力。製藥公司、研究機構和監管機構之間的合作正在促進基於噬菌體的治療方法的開發和核准。由於噬菌體具有精準靶向有害細菌並提供個人化治療方案的獨特能力，預計它們將在未來的抗菌治療策略中發揮關鍵作用。

全球噬菌體市場促進因素

抗生素抗藥性病菌感染的日益增加顯著增加了對替代治療策略的需求。噬菌體是一種能夠選擇性感染並清除特定細菌的病毒，為應對抗生素抗藥性細菌和超級細菌的挑戰提供了潛在的解決方案。隨著傳統抗生素療效的下降，噬菌體市場正蓬勃發展，這主要得益於人們對能夠有效應對這些嚴重健康威脅的創新個人化治療方法的迫切需求。這種向噬菌體療法的轉變凸顯了對抗抗藥性病原體的一種變革性方法，並將噬菌體定位為現代醫學的關鍵資源。

抑制全球噬菌體市場

全球噬菌體市場面臨許多限制因素，主要源自於噬菌體療法中涉及活性病毒。這項特性引發了人們對產品安全性的擔憂，從而構成了許多監管障礙。為確保噬菌體療法的安全性和有效性，需要進行廣泛的測試和核准程序，這既耗時又昂貴。此外，區域監管的不一致性以及不同的要求進一步加劇了這一局面，可能阻礙市場成長和擴大用戶群。這些挑戰共同構成了不利於噬菌體療法在全球發展和推廣的環境。

全球噬菌體市場趨勢

全球噬菌體市場呈現顯著的發展趨勢，這主要得益於人們對創新解決方案以對抗抗藥性感染疾病的需求日益成長。隨著醫療界對傳統抗生素限制的認知不斷加深，噬菌體療法已展現出其特異性靶向並清除抗藥性細菌的能力，成為極具前景的替代方案。噬菌體研究的進展、分離技術的改進以及成功的治療效果，進一步激發了人們對該領域的興趣和投資。此外，患者和醫療服務提供者對噬菌體療法的潛力在療效和安全性的認知不斷提高，也推動了其被廣泛接受，這有望在未來的市場格局中為噬菌體市場帶來顯著的成長和創新。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究

全球噬菌體市場規模（按產品類型和複合年成長率分類）（2026-2033 年）

• 噬菌體益生菌
• 噬菌體療法

全球噬菌體市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 外用
• 其他

全球噬菌體市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 零售藥房
• 醫院藥房
• 網路藥房

全球噬菌體市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 胃腸病學
• 呼吸道感染疾病治療
• 皮膚感染疾病治療
• 傷口預防
• 泌尿系統感染疾病的治療

全球噬菌體市場規模（按終端應用產業分類）及複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 居家醫療
• 其他

全球噬菌體市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Intralytix（United States）
• Proteon Pharmaceuticals（Poland）
• Phagelux（China）
• Micreos（Netherlands）
• Eliava BioPreparations（Georgia）
• Locus Biosciences（United States）
• Pherecydes Pharma（France）
• APS Biocontrol Ltd.（United Kingdom）
• Qingdao Phagepharm Biotech（China）
• Fixed-Phage Limited（United Kingdom）
• Zeptometrix（United States）
• Phage International, Inc.（United States）
• Micromir（Russia）
• Armata Pharmaceuticals, Inc.（United States）
• Nextbiotics（United States）
• InnoPhage, Ltd（Portugal）
• TechnoPhage（Portugal）
• Eligo Bioscience SA（France）
• NPO Microgen（Russia）
• Pharmex Group, LLC（Russia）

結論與建議

Global Bacteriophage Market size was valued at USD 52.43 Million in 2024 and is poised to grow from USD 55.42 Million in 2025 to USD 86.35 Million by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global bacteriophage market is emerging as a vital solution to the pressing issue of antibiotic resistance and bacterial infections. Bacteriophages, which are natural viruses targeting bacteria, present a compelling alternative to conventional antibiotics. The increasing prevalence of antibiotic-resistant bacteria has fueled interest in phage therapy, known for its high specificity, adaptability to evolving bacterial strains, and minimal disruption to beneficial microbiota. Promising results from preclinical and clinical research underscore their therapeutic potential. Collaborations among pharmaceutical companies, research entities, and regulatory bodies are enhancing the development and approval of phage-based therapies. With their unique ability to precisely target harmful bacteria and offer customized treatment approaches, bacteriophages are poised to play a critical role in the future of antimicrobial treatment strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bacteriophage market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bacteriophage Market Segments Analysis

Global Bacteriophage Market is segmented by Product Type, Route of Administration, Distribution Channel, Application, End-use Industry and region. Based on Product Type, the market is segmented into Phage Probiotics and Phage Therapeutics. Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Application, the market is segmented into Gastroenterology, Respiratory Infections Treatment, Skin Infection Treatment, Wound Prophylaxis and Urological Infection Treatment. Based on End-use Industry, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bacteriophage Market

The rising incidence of antibiotic-resistant bacterial infections is significantly boosting the need for alternative treatment strategies. Bacteriophages, which are viruses that selectively infect and eliminate specific bacteria, present a compelling solution for addressing the challenges posed by antibiotic-resistant strains and superbugs. As traditional antibiotics lose their efficacy, the market for bacteriophages is gaining momentum, driven by the urgent demand for innovative and tailored therapeutic options that can effectively tackle these formidable health threats. This shift toward phage therapy highlights a transformative approach in the fight against resistant pathogens, positioning bacteriophages as a crucial resource in modern medicine.

Restraints in the Global Bacteriophage Market

The global bacteriophage market faces significant constraints primarily due to the involvement of live viruses in bacteriophage therapy. This aspect raises various regulatory hurdles stemming from safety concerns surrounding these products. To guarantee both the safety and efficacy of bacteriophage therapies, extensive testing and approval procedures are necessary, which can be both lengthy and financially burdensome. Additionally, regulatory inconsistencies and differing requirements across regions further complicate the situation, potentially obstructing the market's growth and ability to reach broader audiences. These challenges collectively create a less favorable environment for the advancement and acceptance of bacteriophage therapies worldwide.

Market Trends of the Global Bacteriophage Market

The Global Bacteriophage market is witnessing a notable trend driven by the escalating demand for innovative solutions to tackle antibiotic-resistant infections. As the healthcare community increasingly acknowledges the limitations of traditional antibiotics, bacteriophage therapy emerges as a promising alternative, showcasing the ability to specifically target and eliminate resistant bacteria. Advancements in phage research, isolation techniques, and successful therapeutic outcomes are further fueling interest and investment in this field. Additionally, growing awareness among patients and healthcare providers about the potential efficacy and safety of phage therapy is propelling its acceptance, positioning the bacteriophage market for significant growth and innovation in the coming landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Bacteriophage Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Phage Probiotics
• Phage Therapeutics

Global Bacteriophage Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical
• Others

Global Bacteriophage Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Global Bacteriophage Market Size by Application & CAGR (2026-2033)

• Market Overview
• Gastroenterology
• Respiratory Infections Treatment
• Skin Infection Treatment
• Wound Prophylaxis
• Urological Infection Treatment

Global Bacteriophage Market Size by End-use Industry & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Bacteriophage Market Size & CAGR (2026-2033)

• North America (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • US
  • Canada
• Europe (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Route of Administration, Distribution Channel, Application, End-use Industry)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Proteon Pharmaceuticals (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagelux (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliava BioPreparations (Georgia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• APS Biocontrol Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qingdao Phagepharm Biotech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fixed-Phage Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zeptometrix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phage International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micromir (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Armata Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nextbiotics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InnoPhage, Ltd (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NPO Microgen (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmex Group, LLC (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations